Inactivated vaccines may not provide adequate protection in immunosuppressed patients with rheumatic diseases
Open Access
- 11 October 2021
- journal article
- letter
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 81 (2), 295-296
- https://doi.org/10.1136/annrheumdis-2021-221496
Abstract
No abstract availableKeywords
Funding Information
- Indian Rheumatology Association
This publication has 7 references indexed in Scilit:
- SARS-CoV-2 Variants in Patients with ImmunosuppressionThe New England Journal of Medicine, 2021
- Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19The Lancet Microbe, 2021
- AB0546 5 YEARS FOLLOW-UP OF PSORIATIC ARTHRITIS PATIENTS TREATED ACCORDING TREAT-TO-TARGET STRATEGY. PRELIMINARY RESULTSAnnals Of The Rheumatic Diseases, 2021
- Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infectionNature Medicine, 2021
- Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohortAnnals Of The Rheumatic Diseases, 2021
- Comorbidities in rheumatic diseases need special consideration during the COVID-19 pandemicRheumatology International, 2021
- Covid-19 and Kidney TransplantationThe New England Journal of Medicine, 2020